• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login

    • Platelet Aggregation Devices Companies

    ID: MRFR/HC/5981-HCR
    200 Pages
    Rahul Gotadki
    September 2025

    Platelet aggregation devices are used to assess the ability of platelets in blood to aggregate or clump together. These devices are crucial in studying platelet function, which is essential for understanding hemostasis, thrombosis, and related conditions.

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Platelet Aggregation Devices Market Research Report – Forecast till 2035 Infographic
    Summary Table of Contents Segmentation Infographic

    Top Industry Leaders in the Platelet Aggregation Devices Market

    Platelet Aggregation Devices Key CompaniesLatest Platelet Aggregation Devices Companies Update



    • August 2022: OtiTopic, a U.S. respiratory drug development company developing a late-stage inhalable acetylsalicylic acid (ASA) treatment for acute myocardial infarction, was acquired by Philip Morris International Inc. If granted approval, the treatment has the potential to rectify the substantial untreated medical condition that affects more than 83 million individuals in the United States who are classified as having an intermediate to high risk for myocardial infarction. By utilizing its inhalation expertise, scientific knowledge, and capabilities to develop a pipeline of inhaled therapeutics and respiratory drug delivery Beyond Nicotine, PMI intends to accomplish this acquisition as part of its strategic plan. After clinical trials conclude and pending U.S. FDA approvals, PMI will be able to bring ASPRIHALE® to market by leveraging its expertise and the capabilities of other companies in the Beyond Nicotine portfolio.



    • RION AESTHETICS, a market leader in regenerative aesthetics, has introduced CALM, an innovative new post-procedure product included in the (plated)™ Skin Science collection, in January 2023. CALM, being the sole skincare product incorporating RenewosomeTM technology, was intentionally formulated to enhance the patient experience in prestigious aesthetic practices while facilitating post-procedure recuperation. In the practices of our partners, the efficacy of the platelet-derived RenewosomeTM technology facilitates a novel strategy for post-procedure recuperation and improves the overall patient experience. CALM is formulated with an exclusive blend of components to aid in recovery and post-procedure care, as well as to improve overall results. The Platelets on Post Procedure Skin (POPPS) Study, which employs CALM subsequent to a CO2 laser procedure, provides support for the launch.


    List of Platelet Aggregation Devices Key companies in the market


    • Siemens Healthineers




    • Hoffmann-La Roche Ltd




    • Sentinel CH. SpA




    • Sysmex Corporation




    • Werfen




    • Helena Laboratories




    • Bio/Data Corporation




    • Haemonetics Corporation




    • AggreDyne, Inc.




    • Haemochrom Diagnostica GmbH




    • Pathway Diagnostics Limited